{"schema_version":"secwatch.filing_event.v1","accession":"0002070849-26-000048","form_type":"8-K","ticker":"BLLN","cik":"0002070849","company_name":"BillionToOne, Inc.","filed_at":"2026-08-05T20:25:27+00:00","discovered_at":"2026-08-05T20:26:03.678488+00:00","generated_at":"2026-08-05T20:26:07.852608+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"BillionToOne Q2 revenue $109.4M (+64% YoY); net income $8.1M; reiterates FY guidance $450-465M","bullets":["Revenue $109.4M (+64% YoY); prenatal $94.2M (+55%), oncology $13.7M (+176%).","Gross margin 70% (vs 65%); operating income $5.5M vs loss of $1.6M; net income $8.1M ($0.15 EPS).","196,000 tests delivered (+35%); free cash flow $5.1M.","Reiterates FY2026 revenue guidance $450M-$465M (48-52% growth).","Announces expanded Unity Fetal Risk Screen (130-gene panel) and Northstar Origin launch."],"urls":{"canonical":"https://secwatch.observer/filing/0002070849-26-000048","json":"https://secwatch.observer/filing/0002070849-26-000048.json","markdown":"https://secwatch.observer/filing/0002070849-26-000048.md","text":"https://secwatch.observer/filing/0002070849-26-000048.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2070849/000207084926000048/0002070849-26-000048-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2070849/000207084926000048/blln-20260805.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-05T20:26:07.852608+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}